Related Experiment Video
Updated: May 20, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Adjuvant therapy of pancreatic cancer
Chakra P Chaulagain1, John Ng, David Wazer
1Division of Hematology and Oncology, Department of Radiation Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA. cchaulagain@tuftsmedicalcenter.org
Abstract:
Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, USA. We present the summary of the findings from Abstracts #4020, #4021, #4040 and #4049 and discuss the impact on this group of patients.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Tumor Immunotherapy
Treatment Resistent Cancers
